LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PETHEMA Foundation
This is a clinical trial with a pharmaceutical drug used in the same conditions of authorization.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with HIV infection diagnosed with DLBCL in any stage (I-IV according to the Ann Arbor classification) not previously treated for the lymphoma.
Patients with CD20-positive diffuse large B-cell lymphoma
Aged from 18 to 70 years old
Any score of International Prognostic Index. (It is also applicable in patients with non-Hodgkin lymphoma \[NHL\] infected with HIV.)
ECOG performance status 0 to 3
Written informed consent
Absolute neutrophil count \> 1.5 x 10\^9/L.
Absence of synchronic or non-synchronic neoplasia with the exception of non-melanoma skin tumors or in situ cervical carcinoma.
CD4+ lymphocyte count \> 100/µL
You may not be if
Patients with diffuse large B cell lymphoma previously treated.
Patients with primary central nervous system lymphoma.
Patients with Burkitt or Burkitt-like NHL.
CD4+ lymphocyte count \< 100/µL
Opportunistic infections or other AIDS-related neoplasias in activity.
Active drug-addiction.
Pregnant or lactating women or adults of fertile age who do not use an effective contraceptive method.
Patients with serious altered renal function (creatinine \> 2.5 x upper limit of normal \[ULN\]) or hepatic \[bilirubin, ALT or AST \> 2.5 x ULN\], except if the investigators suspect that they are caused by the disease.
Cardiac insufficiency with ejection fraction \< 40%
Patients with serious psychiatric diseases that can interfere with their capacity to understand the study (including alcoholism or active drug-addiction).
ECOG \> 3
Patients with a known hypersensitivity to murine proteins or any other component of the study drugs.
Clareo Health | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
